The drop follows a series of downward revisions regarding the company's financial health. In February, Teladoc projected full-year revenue between $2.47 billion and $2.59 billion. By April, those expectations were tightened as the company struggled with its BetterHelp division. CEO Charles Divita previously cited an accelerated decline in cash-paying users and difficulties scaling insurance capacity as primary factors behind the shifting outlook.
In section Releases
Teladoc Shares Plummet Following Revenue Guidance Cut
Teladoc Health stock plunged more than 28% after the company reported second-quarter revenue of $606.9 million, missing analyst expectations. Following the shortfall, the firm lowered its full-year 2026 revenue forecast to a range between $2.36 billion and $2.45 billion, prompting a securities investigation by Levi & Korsinsky.
Levi & Korsinsky is currently examining whether the company issued materially false or misleading statements regarding its forward-looking revenue projections. Investors who purchased shares and suffered financial losses are being encouraged to submit their transaction records for a no-cost evaluation. The investigation focuses on whether shareholders were adequately informed of the risks facing the BetterHelp segment and the broader business model throughout the year.
Comments (0)
No comments yet. Be the first!